今日焦点！上期所调整丁二烯橡胶期货BR2407、BR2408合约日内平今仓交易手续费

上期所调整丁二烯橡胶期货BR2407、BR2408合约日内平今仓交易手续费

上海，2024年6月18日 - 为了进一步完善丁二烯橡胶期货市场功能，降低投资者交易成本，上海期货交易所（上期所）决定自2024年6月18日交易（即6月17日晚夜盘）起，调整丁二烯橡胶期货BR2407、BR2408合约日内平今仓交易手续费为成交金额的万分之一。

此次调整是上期所贯彻落实期货市场降费减负政策的又一重要举措。此前，上期所已多次下调丁二烯橡胶期货交易手续费，有效降低了投资者的交易成本，受到了市场各方欢迎。

业内人士表示，此次调整将进一步降低丁二烯橡胶期货合约日内平今仓交易成本，激发市场活力，促进期货市场平稳运行。

具体调整内容如下：

合约调整前手续费调整后手续费BR2407成交金额的万分之二成交金额的万分之一BR2408成交金额的万分之二成交金额的万分之一drive_spreadsheetExport to Sheets

调整后的手续费费率低于现行费率的50%，将为投资者节省大量交易成本。

以下是一些对该新闻的补充说明：

• 丁二烯橡胶期货是上期所于2010年推出的期货品种，主要服务于丁二烯橡胶产业链上下游企业。
• 日内平今仓交易是指投资者在同一交易日内买入并卖出同一合约，或卖出并买入同一合约的行为。
• 交易手续费是投资者在期货交易所进行交易时所支付的费用，是期货交易所的重要收入来源。

此次调整是上期所践行“稳中求进”工作总基调，持续深化期货市场改革开放，更好服务实体经济的具体体现。

希望以上信息对您有所帮助。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.